When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BHC - Incyte details late-stage data on ruxolitinib cream for atopic dermatitis
Bausch Health Companies Inc.
Following up on its initial announcements in January and February, Incyte (NASDAQ:INCY) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2, evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults with atopic dermatitis (AD). The data were presented at the Revolutionizing Atopic Dermatitis Virtual Symposium.
More news on: Incyte Corporation, Pfizer Inc., Dermira, Inc., Healthcare stocks news,